ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2878

G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans

Teresa K. Tarrant1, D. Stephen Serafin2, Elizabeth Sugg2, Roman Timoshchenko2, Matthew J. Billard2, David P. Siderovski3 and Kristy Richards4, 1Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, 4Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Gene Expression, inflammatory arthritis and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose

GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes.  We have shown that Gpsm3 deficient (-/-) mice are protected from Collagen Antibody Induced Arthritis due in part to their attenuated monocyte responses, including decreased ex vivo migration to the chemokines CX3CL1, CCL2, and chemerin, and enhanced apoptosis, which leads to an observed decrease in proinflammatory intra-articular IL-6 and IL-1b transcripts in the joint.  Given the restricted expression of GPSM3 in leukocytes and the functional phenotypes observed in immune cells lacking GPSM3 expression, we chose to examine effects of GPSM3 deficiency in Collagen Induced Arthritis (CIA) and to analyze whether single nucleotide polymorphisms (SNPs) within the human GPSM3 gene locus, associated with a decreased incidence of autoimmunity, correlate with altered GPSM3 gene products.  

Methods

Gpsm3-/- and Gpsm3+/+ DBA1-J mice were immunized with heterologous type II collagen in Freund’s Adjuvant with a booster immunization at day 21 per published protocols.  Arthritis was assessed by a blinded observer for paw swelling and clinical disease score (0-4). Paws were processed at day 42 for histopathology.  Serum B-cell activating factor (BAFF) was measured by commercial ELISA (R&D Systems) per manufacturer’s instructions on day 14.  DNA and RNA was isolated from healthy human subject blood using Qiagen purification reagents. Genotyping for SNP (A (minor) / G (major) transition substitution) was performed using commercially available TaqMan SNP Genotyping Assay (SNP ID = rs204989) from Applied Biosystems by Life Technologies.  qRT-PCR primers for known GPSM3 transcripts -001, -002, -003, and -004 were designed from NCBI (-001 and -002) and Ensembl (-003 and -004) databases, and validated by gel electrophoresis for sequence length, sequencing, melt curve analysis, and PrimerBlast. qRT-PCR of cDNA from healthy human subject blood was performed using a Biorad CFX96 Real-Time System and standard protocols.  Data was calculated as relative expression compared to the housekeeping gene IDUA(ΔCt).

Results

Gpsm3-/- mice are protected from CIA and have significantly decreased serum BAFF levels.  Healthy human subjects carrying protective SNP alleles that correlate with a decreased incidence of rheumatoid arthritis (RA) and four other autoimmune diseases have decreased levels of transcripts GPSM3-001, -002, and -004, but significantly increased levels of the transcript GPSM3-003, which is thought to be subjected to nonsense-mediated decay.

Conclusion

Our goal from these studies is to determine whether GPSM3 has immune system-modulating potential for the treatment of autoimmune diseases with particular focus on inflammatory arthritis.  Gpsm3-/- mice are protected from two models of inflammatory arthritis through mechanisms involving monocyte function. GPSM3 has altered mRNA transcripts in healthy human subjects with SNPs that correlate with decreased RA and other autoimmune diseases, suggesting differential gene regulation.


Disclosure:

T. K. Tarrant,
None;

D. S. Serafin,
None;

E. Sugg,
None;

R. Timoshchenko,
None;

M. J. Billard,
None;

D. P. Siderovski,
None;

K. Richards,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/g-protein-signaling-modulator-3-gpsm3-deficiency-is-protective-in-inflammatory-arthritis-models-and-altered-gpsm3-gene-products-correlate-with-single-nucleotide-polymorphisms-in-humans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology